Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1988 Feb;85(4):1189–1193. doi: 10.1073/pnas.85.4.1189

Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.

H M Yang 1, R A Reisfeld 1
PMCID: PMC279732  PMID: 3422487

Abstract

Doxorubicin (DXR) was covalently conjugated to a monoclonal antibody (mAb), 9.2.27 (IgG2a), which recognizes a chondroitin sulfate proteoglycan expressed preferentially on the surface of human melanoma cells. Immunoconjugates with a molar ratio of DXR to mAb ranging from 2:1 to 10:1 were obtained by coupling the drug via an acid-sensitive linker, cis-aconitic anhydride. The immunoreactivity of mAb 9.2.27 was well retained after conjugation. DXR-mAb 9.2.27 conjugates were found to be 2 orders of magnitude more potent in killing tumor cells in vitro (IC50 = 0.1 microM) than free drug targeted to drug receptor(s). Most significantly, DXR-mAb 9.2.27 immunoconjugates specifically suppressed the growth of established tumors in vivo and prolonged the life-span of tumor-bearing nude mice. This suppression of melanoma growth achieved by the immunoconjugate was both tumor and antibody specific. A biodistribution study indicated that DXR-mAb 9.2.27 conjugates delivered at least 4 times more DXR (3.7% total injected dose per g of tumor) as compared to free DXR alone (0.8% total injected dose per g of tumor) in tumor-bearing nude mice 48 hr postinjection. The tumor-suppressive effects of DXR-mAb 9.2.27 conjugates are even more remarkable since free DXR did not suppress tumor growth in vivo and also because this drug per se is known to be quite ineffective for the treatment of human melanoma.

Full text

PDF
1189

Images in this article

1191Image
on p.1191
1191Image
on p.1191
1191Image
on p.1191

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  2. Bumol T. F., Reisfeld R. A. Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci U S A. 1982 Feb;79(4):1245–1249. doi: 10.1073/pnas.79.4.1245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bumol T. F., Wang Q. C., Reisfeld R. A., Kaplan N. O. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc Natl Acad Sci U S A. 1983 Jan;80(2):529–533. doi: 10.1073/pnas.80.2.529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Deguchi T., Chu T. M., Leong S. S., Horoszewicz J. S., Lee C. L. Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor. Cancer Res. 1986 Aug;46(8):3751–3755. [PubMed] [Google Scholar]
  5. Diener E., Diner U. E., Sinha A., Xie S., Vergidis R. Specific immunosuppression by immunotoxins containing daunomycin. Science. 1986 Jan 10;231(4734):148–150. doi: 10.1126/science.3484557. [DOI] [PubMed] [Google Scholar]
  6. Durand R. E., Olive P. L. Flow cytometry studies of intracellular adriamycin in single cells in vitro. Cancer Res. 1981 Sep;41(9 Pt 1):3489–3494. [PubMed] [Google Scholar]
  7. Ey P. L., Prowse S. J., Jenkin C. R. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry. 1978 Jul;15(7):429–436. doi: 10.1016/0161-5890(78)90070-6. [DOI] [PubMed] [Google Scholar]
  8. Giuliani F. C., Kaplan N. O. New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse. Cancer Res. 1980 Dec;40(12):4682–4687. [PubMed] [Google Scholar]
  9. Harper J. R., Orengo A. The preparation of an immunoglobulin--amyloglucosidase conjugate and its quantitation by an enzyme-cycling assay. Anal Biochem. 1981 May 1;113(1):51–57. doi: 10.1016/0003-2697(81)90042-7. [DOI] [PubMed] [Google Scholar]
  10. Honsik C. J., Jung G., Reisfeld R. A. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci U S A. 1986 Oct;83(20):7893–7897. doi: 10.1073/pnas.83.20.7893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lashford L., Jones D., Pritchard J., Gordon I., Breatnach F., Kemshead J. T. Therapeutic application of radiolabeled monoclonal antibody UJ13A in children with disseminated neuroblastoma. NCI Monogr. 1987;(3):53–57. [PubMed] [Google Scholar]
  12. Lindmo T., Davies C., Rofstad E. K., Fodstad O., Sundan A. Antigen expression in human melanoma cells in relation to growth conditions and cell-cycle distribution. Int J Cancer. 1984 Feb 15;33(2):167–171. doi: 10.1002/ijc.2910330203. [DOI] [PubMed] [Google Scholar]
  13. Mayhew E. G., Goldrosen M. H., Vaage J., Rustum Y. M. Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. J Natl Cancer Inst. 1987 Apr;78(4):707–713. [PubMed] [Google Scholar]
  14. Oldham R. K., Foon K. A., Morgan A. C., Woodhouse C. S., Schroff R. W., Abrams P. G., Fer M., Schoenberger C. S., Farrell M., Kimball E. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol. 1984 Nov;2(11):1235–1244. doi: 10.1200/JCO.1984.2.11.1235. [DOI] [PubMed] [Google Scholar]
  15. Pastan I., Willingham M. C., FitzGerald D. J. Immunotoxins. Cell. 1986 Dec 5;47(5):641–648. doi: 10.1016/0092-8674(86)90506-4. [DOI] [PubMed] [Google Scholar]
  16. Sandvig K., Olsnes S. Diphtheria toxin entry into cells is facilitated by low pH. J Cell Biol. 1980 Dec;87(3 Pt 1):828–832. doi: 10.1083/jcb.87.3.828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Schneider Y. J., Baurain R., Zenebergh A., Trouet A. DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro. Cancer Chemother Pharmacol. 1979;2(1):7–10. doi: 10.1007/BF00253097. [DOI] [PubMed] [Google Scholar]
  18. Shen W. C., Ryser H. J. cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem Biophys Res Commun. 1981 Oct 15;102(3):1048–1054. doi: 10.1016/0006-291x(81)91644-2. [DOI] [PubMed] [Google Scholar]
  19. Tobey R. A., Crissman H. A., Oka M. S. Arrested and cycling CHO cells as a kinetic model: studies with adriamycin. Cancer Treat Rep. 1976 Dec;60(12):1829–1837. [PubMed] [Google Scholar]
  20. Uadia P., Blair A. H., Ghose T. Tumor and tissue distribution of a methotrexate-anti-EL4 immunoglobulin conjugate in EL4 lymphoma-bearing mice. Cancer Res. 1984 Oct;44(10):4263–4266. [PubMed] [Google Scholar]
  21. Zunino F., Gambetta R., Di Marco A., Zaccara A. Interaction of daunomycin and its derivatives with DNA. Biochim Biophys Acta. 1972 Sep 14;277(3):489–498. doi: 10.1016/0005-2787(72)90092-5. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES